Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

100.54USD
5 Feb 2016
Change (% chg)

$-3.36 (-3.23%)
Prev Close
$103.90
Open
$102.77
Day's High
$102.77
Day's Low
$99.78
Volume
3,803,118
Avg. Vol
2,990,749
52-wk High
$105.48
52-wk Low
$81.79

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $278,188.50
Shares Outstanding(Mil.): 2,766.94
Dividend: 0.75
Yield (%): 2.98

Financials

  JNJ.N Industry Sector
P/E (TTM): 18.35 31.82 38.73
EPS (TTM): 5.48 -- --
ROI: -- 15.16 14.47
ROE: -- 15.92 15.40
Search Stocks

Pfizer, J&J, Merck evaluating technologies for Zika vaccine

Pfizer Inc, Johnson and Johnson and Merck & Co Inc said they were evaluating their technologies or existing vaccines for their potential to combat Zika, a rapidly spreading mosquito-borne disease linked to birth defects.

03 Feb 2016

Pfizer, J&J, Merck evaluating technologies for Zika vaccine

Feb 3 Pfizer Inc, Johnson and Johnson and Merck & Co Inc said they were evaluating their technologies or existing vaccines for their potential to combat Zika, a rapidly spreading mosquito-borne disease linked to birth defects.

03 Feb 2016

Investor pressures J&J to consider split up -sources

Jan 27 Artisan Partners, a major shareholder in Johnson & Johnson, has urged several activists to pressure the consumer products giant to consider major changes that include a potential split, according to sources and documents.

28 Jan 2016

UPDATE 3-J&J profit beats forecasts, helped by lower taxes, cost cuts

Jan 26 Johnson & Johnson on Tuesday reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, and gave a 2016 profit outlook slightly above Wall Street's.

27 Jan 2016

BRIEF-Imperial Innovations joins consortium to launch 40 mln stg therapeutics fund

* Innovations joins consortium of three world-leading UK universities and three global pharmaceutical companies to launch 40 million pounds ($57.22 million) therapeutics fund

25 Jan 2016

J&J to cut 3,000 jobs in struggling device division

Johnson & Johnson said on Tuesday it would cut about 3,000 jobs within its medical devices unit over the next two years, or about 4 to 6 percent of the struggling division's global workforce, to generate annual cost savings of up to $1 billion and focus on more innovative products.

20 Jan 2016

UPDATE 3-U.S. top court won't hear J&J appeal of $140 million judgment

NEW YORK, Jan 19 The U.S. Supreme Court said on Tuesday it will not hear Johnson & Johnson's appeal of a $140 million judgment in a lawsuit alleging it failed to warn that Children's Motrin pain and fever medication could cause a devastating skin condition.

19 Jan 2016

U.S. justices reject Johnson & Johnson unit's anti-psychotic drug appeal

WASHINGTON The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary's appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its risks.

11 Jan 2016

UPDATE 1-U.S. justices reject Johnson & Johnson unit's anti-psychotic drug appeal

WASHINGTON, Jan 11 The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary's appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its risks.

11 Jan 2016

U.S. top court rejects Johnson & Johnson unit's appeal of $124 mln penalty

WASHINGTON, Jan 11 The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary's appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its risks.

11 Jan 2016

Earnings vs. Estimates

Search Stocks